Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Globally, colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the
second leading cause of cancer death. Arising through three major pathways, including …

Colorectal cancer (CRC) is a predominant life‐threatening cancer, with liver and peritoneal
metastases as the primary causes of death. Intestinal inflammation, a known CRC risk factor …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …

Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis
of this variability remains poorly understood. We performed prospective targeted sequencing …

Background There is increasing evidence that metastatic colorectal cancer (mCRC) is a
genetically heterogeneous disease and that tumours arising from different sides of the colon …

Critical driver genomic events in colorectal cancer have been shown to affect the response
to targeted agents that were initially developed under the'one gene, one drug'paradigm of …

Importance Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors
arising from different regions of the colon are clinically and molecularly distinct. Objective To …

Human epidermal growth factor receptor 2 (HER2) is a well-known oncogenic driver in
different tumors and an approved therapeutic target in breast and gastroesophageal cancer …